Cargando…

Treatment of Parkinson’s disease in the advanced stage

Levodopa/Carbidopa, respectively, Levodopa/Benserazide is the most effective treatment for Parkinson’s disease and during the progress of the disease, patients will inevitably need to be treated with it. Nonetheless, after a certain time period most of the patients experience side effects. Mainly di...

Descripción completa

Detalles Bibliográficos
Autores principales: Ossig, C., Reichmann, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3611036/
https://www.ncbi.nlm.nih.gov/pubmed/23474822
http://dx.doi.org/10.1007/s00702-013-1008-y
_version_ 1782264528252174336
author Ossig, C.
Reichmann, H.
author_facet Ossig, C.
Reichmann, H.
author_sort Ossig, C.
collection PubMed
description Levodopa/Carbidopa, respectively, Levodopa/Benserazide is the most effective treatment for Parkinson’s disease and during the progress of the disease, patients will inevitably need to be treated with it. Nonetheless, after a certain time period most of the patients experience side effects. Mainly disturbing are motor and non-motor fluctuations and dyskinesia. Numerous options from changing the medication regimen, to continuos dopaminergic drug delivery via apomorphine or Duodopa pumps and stereotactical interventions are available. The physician’s responsibility is to choose the right therapeutic procedure for each timepoint of the patient’s disease. In this review, we provide an up to date overview of the available strategies.
format Online
Article
Text
id pubmed-3611036
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-36110362013-04-01 Treatment of Parkinson’s disease in the advanced stage Ossig, C. Reichmann, H. J Neural Transm (Vienna) Neurology and Preclinical Neurological Studies - Review Article Levodopa/Carbidopa, respectively, Levodopa/Benserazide is the most effective treatment for Parkinson’s disease and during the progress of the disease, patients will inevitably need to be treated with it. Nonetheless, after a certain time period most of the patients experience side effects. Mainly disturbing are motor and non-motor fluctuations and dyskinesia. Numerous options from changing the medication regimen, to continuos dopaminergic drug delivery via apomorphine or Duodopa pumps and stereotactical interventions are available. The physician’s responsibility is to choose the right therapeutic procedure for each timepoint of the patient’s disease. In this review, we provide an up to date overview of the available strategies. Springer Vienna 2013-03-10 2013 /pmc/articles/PMC3611036/ /pubmed/23474822 http://dx.doi.org/10.1007/s00702-013-1008-y Text en © The Author(s) 2013 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Neurology and Preclinical Neurological Studies - Review Article
Ossig, C.
Reichmann, H.
Treatment of Parkinson’s disease in the advanced stage
title Treatment of Parkinson’s disease in the advanced stage
title_full Treatment of Parkinson’s disease in the advanced stage
title_fullStr Treatment of Parkinson’s disease in the advanced stage
title_full_unstemmed Treatment of Parkinson’s disease in the advanced stage
title_short Treatment of Parkinson’s disease in the advanced stage
title_sort treatment of parkinson’s disease in the advanced stage
topic Neurology and Preclinical Neurological Studies - Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3611036/
https://www.ncbi.nlm.nih.gov/pubmed/23474822
http://dx.doi.org/10.1007/s00702-013-1008-y
work_keys_str_mv AT ossigc treatmentofparkinsonsdiseaseintheadvancedstage
AT reichmannh treatmentofparkinsonsdiseaseintheadvancedstage